Olmesartan attenuates type 2 diabetes-associated liver injury: Cross-talk of AGE/RAGE/JNK, STAT3/SCOS3 and RAS signaling pathways. [electronic resource]
Producer: 20201201Description: 173010 p. digitalISSN:- 1879-0712
- Angiotensin II Type 1 Receptor Blockers -- pharmacology
- Animals
- Blood Glucose -- analysis
- Diabetes Complications -- drug therapy
- Diabetes Mellitus, Experimental -- drug therapy
- Diabetes Mellitus, Type 2 -- drug therapy
- Glycation End Products, Advanced -- metabolism
- Hypoglycemic Agents -- pharmacology
- Imidazoles -- pharmacology
- Insulin -- blood
- Insulin Resistance
- JNK Mitogen-Activated Protein Kinases -- metabolism
- Liver -- drug effects
- Liver Diseases -- drug therapy
- Male
- Rats, Wistar
- Receptor for Advanced Glycation End Products -- metabolism
- Renin-Angiotensin System
- STAT3 Transcription Factor -- metabolism
- Signal Transduction -- drug effects
- Tetrazoles -- pharmacology
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.